Patricia Gómez-Molina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Patricia Gómez-Molina has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Sanz-Bravo
From the ‡Centro de Biología Molecular Severo Ochoa (CSIC-UAM), 28049 Madrid, Spain
3 shared publications - José Antonio López de Castro
Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid), Universidad Autónoma, Madrid, Spain
3 shared publications - Miguel Marcilla
Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain
3 shared publications Noel García-Medel
From the ‡Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid), Madrid, Spain
3 shared publications- Arie Admon
Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel
2 shared publications Begoña Galocha
From the ‡Centro de Biología Molecular Severo Ochoa, CSIC-UAM, 28049 Madrid, Spain
2 shared publications
Latest Publications
- 25 January 2016
- Published by Wiley in Arthritis & Rheumatology
- Vol. 68 (2) , 505-515
The Peptidome of Behçet's Disease–Associated HLA–B*51:01 Includes Two Subpeptidomes Differentially Shaped by Endoplasmic Reticulum Aminopeptidase 1
Objective: To characterize the peptidome of the Behçet's disease–associated HLA–B*51:01 allotype as well as the differential features of major peptide subsets and their distinct endoplasmic reticulum aminopeptidase 1 (ERAP‐1)–mediated processing.Methods: The endogenous B*51:01‐bound peptidome was characterized from 721.221 transfectant cells, after affinity chromatography and acid extraction, by tandem mass spectrometry. Recombinant ERAP‐1 variants were used to digest synthetic B*51:01 ligands. HLA and transporter associated with antigen processing (TAP) binding affinities of peptide ligands were calculated with well‐established algorithms. ERAP‐1 and ERAP‐2 from 721.221 cells were characterized by genomic sequencing and Western blotting.Results: The B*51:01 peptidome consisted of 29.5% octamers, 61.7% nonamers, 4.8% decamers, and 4.0% longer peptides. The major peptide motif consisted of Pro and Ala at position 2, aliphatic/aromatic position 3 residues, and Val and Ile at the C‐terminal position. The ligands with Pro or Ala at position 2 constituted 2 distinct subpeptidomes. Peptides with Pro at position 2 showed higher affinity for B*51:01 and lower affinity for TAP than those with Ala at position 2. Most important, both peptide subsets differed drastically in the susceptibility of their position 1 residues to ERAP‐1, revealing a distinct influence of this enzyme on both subpeptidomes, which may alter their balance, affecting the global affinity of B*51:01–peptide complexes.Conclusion: ERAP‐1 has a significant influence on the B*51:01 peptidome and its affinity. This influence is based on very distinct effects on the 2 subpeptidomes, whereby only peptides in the subpeptidome with Ala at position 2 are extensively destroyed, except when their position 1 residues are ERAP‐1 resistant. This pattern provides a mechanism for the epistatic association of ERAP‐1 and B*51:01 in Behçet's disease.
- 25 January 2016
- Published by Wiley in Arthritis & Rheumatology
- Vol. 68 (2) , 505-515
The Peptidome of Behçet's Disease–Associated HLA–B*51:01 Includes Two Subpeptidomes Differentially Shaped by Endoplasmic Reticulum Aminopeptidase 1
Objective: To characterize the peptidome of the Behçet's disease–associated HLA–B*51:01 allotype as well as the differential features of major peptide subsets and their distinct endoplasmic reticulum aminopeptidase 1 (ERAP‐1)–mediated processing.Methods: The endogenous B*51:01‐bound peptidome was characterized from 721.221 transfectant cells, after affinity chromatography and acid extraction, by tandem mass spectrometry. Recombinant ERAP‐1 variants were used to digest synthetic B*51:01 ligands. HLA and transporter associated with antigen processing (TAP) binding affinities of peptide ligands were calculated with well‐established algorithms. ERAP‐1 and ERAP‐2 from 721.221 cells were characterized by genomic sequencing and Western blotting.Results: The B*51:01 peptidome consisted of 29.5% octamers, 61.7% nonamers, 4.8% decamers, and 4.0% longer peptides. The major peptide motif consisted of Pro and Ala at position 2, aliphatic/aromatic position 3 residues, and Val and Ile at the C‐terminal position. The ligands with Pro or Ala at position 2 constituted 2 distinct subpeptidomes. Peptides with Pro at position 2 showed higher affinity for B*51:01 and lower affinity for TAP than those with Ala at position 2. Most important, both peptide subsets differed drastically in the susceptibility of their position 1 residues to ERAP‐1, revealing a distinct influence of this enzyme on both subpeptidomes, which may alter their balance, affecting the global affinity of B*51:01–peptide complexes.Conclusion: ERAP‐1 has a significant influence on the B*51:01 peptidome and its affinity. This influence is based on very distinct effects on the 2 subpeptidomes, whereby only peptides in the subpeptidome with Ala at position 2 are extensively destroyed, except when their position 1 residues are ERAP‐1 resistant. This pattern provides a mechanism for the epistatic association of ERAP‐1 and B*51:01 in Behçet's disease.
- Open Access
- 1 December 2014
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 13 (12) , 3367-3380
Peptide Handling by HLA-B27 Subtypes Influences Their Biological Behavior, Association with Ankylosing Spondylitis and Susceptibility to Endoplasmic Reticulum Aminopeptidase 1 (ERAP1)
- 1 December 2014
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 13 (12) , 3367-3380
Open AccessPeptide Handling by HLA-B27 Subtypes Influences Their Biological Behavior, Association with Ankylosing Spondylitis and Susceptibility to Endoplasmic Reticulum Aminopeptidase 1 (ERAP1)
- Open Access
- 1 February 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (7) , 3978-3990
Combined Effects of Ankylosing Spondylitis-associated ERAP1 Polymorphisms Outside the Catalytic and Peptide-binding Sites on the Processing of Natural HLA-B27 Ligands
- 1 February 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (7) , 3978-3990
Open AccessCombined Effects of Ankylosing Spondylitis-associated ERAP1 Polymorphisms Outside the Catalytic and Peptide-binding Sites on the Processing of Natural HLA-B27 Ligands
- Open Access
- 1 November 2012
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 11 (11) , 1416-1429
Functional Interaction of the Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 1 Polymorphism and HLA-B27 in Vivo
- 1 November 2012
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 11 (11) , 1416-1429
Open AccessFunctional Interaction of the Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 1 Polymorphism and HLA-B27 in Vivo
- 1 January 2009
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 182 (1) , 446-455
Presentation of Cytosolically Stable Peptides by HLA-B27 Is Not Dependent on the Canonic Interactions of N-Terminal Basic Residues in the A Pocket
HLA-B27 binds peptides with R at position 2. Additionally, a substantial fraction of the HLA-B27-bound peptide repertoire has basic residues at position 1. It is unclear whether this is determined by structural complementarity with the A pocket of the peptide-binding site, by the increased availability of peptides with dibasic N-terminal sequences resulting from their cytosolic stability, or both. To distinguish between these possibilities two B*2705 mutants were generated in which one or two A pocket surface residues stabilizing the peptidic R1 side chain were changed: E163T and E163T-W167S. Both mutants bound a large fraction of the constitutive peptide repertoire of B*2705. Moreover, 90 B*2705 ligands of known sequence were examined for their endogenous presentation by the mutants. The E163T mutation alone had a limited effect on binding of peptides with R1 or K1 and on the relative frequencies of N-terminal residues. However, it decreased the overall stability of the molecule. The E163T-W167S mutant also bound many of the B*2705 ligands with N-terminal basic residues, but its preference for G1 was significantly decreased. The results indicate that the capacity of HLA-B27 to bind peptides with N-terminal basic residues is largely independent of the canonic interactions that stabilize at least the R1 side chain. Thus, the prevalence of HLA-B27 ligands with dibasic N-terminal sequences may be significantly influenced by the increased availability of these peptides resulting from their cytosolic stability. This confers to HLA-B27 a unique capacity to present Ags generated in low amounts, but resistant to intracellular degradation.
- 1 January 2009
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 182 (1) , 446-455
Presentation of Cytosolically Stable Peptides by HLA-B27 Is Not Dependent on the Canonic Interactions of N-Terminal Basic Residues in the A Pocket
HLA-B27 binds peptides with R at position 2. Additionally, a substantial fraction of the HLA-B27-bound peptide repertoire has basic residues at position 1. It is unclear whether this is determined by structural complementarity with the A pocket of the peptide-binding site, by the increased availability of peptides with dibasic N-terminal sequences resulting from their cytosolic stability, or both. To distinguish between these possibilities two B*2705 mutants were generated in which one or two A pocket surface residues stabilizing the peptidic R1 side chain were changed: E163T and E163T-W167S. Both mutants bound a large fraction of the constitutive peptide repertoire of B*2705. Moreover, 90 B*2705 ligands of known sequence were examined for their endogenous presentation by the mutants. The E163T mutation alone had a limited effect on binding of peptides with R1 or K1 and on the relative frequencies of N-terminal residues. However, it decreased the overall stability of the molecule. The E163T-W167S mutant also bound many of the B*2705 ligands with N-terminal basic residues, but its preference for G1 was significantly decreased. The results indicate that the capacity of HLA-B27 to bind peptides with N-terminal basic residues is largely independent of the canonic interactions that stabilize at least the R1 side chain. Thus, the prevalence of HLA-B27 ligands with dibasic N-terminal sequences may be significantly influenced by the increased availability of these peptides resulting from their cytosolic stability. This confers to HLA-B27 a unique capacity to present Ags generated in low amounts, but resistant to intracellular degradation.
- 30 June 2006
- Published by Wiley in European Journal of Immunology
- Vol. 36 (7) , 1867-1881
B*2707 differs in peptide specificity from B*2705 and B*2704 as much as from HLA‐B27 subtypes not associated to spondyloarthritis
HLA‐B*2707 is associated with ankylosing spondylitis in most populations. Like the non‐associated allotypes B*2706 and B*2709, it lacks Asp116 and shows preference for peptides with nonpolar C‐terminal residues. The relationships between the peptide specificity of B*2707 and those of the disease‐associated B*2705 and the non‐associated subtypes were analyzed by determining the overlap between the corresponding peptide repertoires, the sequence of shared and differential ligands, and by comparing allospecific T cell epitopes with peptide sharing. The B*2707‐bound repertoire was as different from that of B*2705 as from those of B*2706, B*2709, or the two latter subtypes from each other. Differences between B*2707 and B*2705 were based on their C‐terminal residue specificity and a subtle modulation at other positions. Differential usage of secondary anchor residues explained the disparity between the B*2707‐, B*2706‐, and B*2709‐bound repertoires. Similar differences in residue usage were found between B*2707 and both B*2704 and B*2706, as expected from the high peptide overlap between the two latter subtypes. T cell cross‐reaction paralleled peptide sharing, suggesting that many shared ligands conserve their alloantigenic features on distinct subtypes. Our results indicate that association of HLA‐B27 subtypes with ankylosing spondylitis does not correlate with higher peptide sharing among disease‐associated subtypes or with obvious peptide motifs.
- 30 June 2006
- Published by Wiley in European Journal of Immunology
- Vol. 36 (7) , 1867-1881
B*2707 differs in peptide specificity from B*2705 and B*2704 as much as from HLA‐B27 subtypes not associated to spondyloarthritis
HLA‐B*2707 is associated with ankylosing spondylitis in most populations. Like the non‐associated allotypes B*2706 and B*2709, it lacks Asp116 and shows preference for peptides with nonpolar C‐terminal residues. The relationships between the peptide specificity of B*2707 and those of the disease‐associated B*2705 and the non‐associated subtypes were analyzed by determining the overlap between the corresponding peptide repertoires, the sequence of shared and differential ligands, and by comparing allospecific T cell epitopes with peptide sharing. The B*2707‐bound repertoire was as different from that of B*2705 as from those of B*2706, B*2709, or the two latter subtypes from each other. Differences between B*2707 and B*2705 were based on their C‐terminal residue specificity and a subtle modulation at other positions. Differential usage of secondary anchor residues explained the disparity between the B*2707‐, B*2706‐, and B*2709‐bound repertoires. Similar differences in residue usage were found between B*2707 and both B*2704 and B*2706, as expected from the high peptide overlap between the two latter subtypes. T cell cross‐reaction paralleled peptide sharing, suggesting that many shared ligands conserve their alloantigenic features on distinct subtypes. Our results indicate that association of HLA‐B27 subtypes with ankylosing spondylitis does not correlate with higher peptide sharing among disease‐associated subtypes or with obvious peptide motifs.